RT Journal Article
SR Electronic
T1 Stopping the misinformation: BNT162b2 COVID-19 vaccine has no negative effect on women’s fertility
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.30.21258079
DO 10.1101/2021.05.30.21258079
A1 Safrai, Myriam
A1 Rottenstreich, Amihai
A1 Herzberg, Shmuel
A1 Imbar, Tal
A1 Reubinoff, Benjamin
A1 Ben-Meir, Assaf
YR 2021
UL http://medrxiv.org/content/early/2021/06/01/2021.05.30.21258079.abstract
AB Objective To investigate the possible impact of Pfizer-BioNTech’s mRNA BNT162b2 COVID-19 vaccine on women’s fertility.Methods A retrospective single-center study examining women’s IVF treatment parameters and pregnancies before and after their vaccination between February and May 2021. Each woman served as a self-control before and after vaccination. Additionally, in order to neutralize the effect of the sperm on fertilization, only Intracytoplasmic Sperm Injection (ICSI) patients who were currently being treated with an ICSI cycle and had an earlier ICSI cycle available were included in the study. The study outcomes compared between the PRE and POST vaccination groups and consisted of: the IVF cycle outcomes, including the number of oocytes retrieved; the number of matured oocytes; the fertilization rate; and the number and quality of embryos at day 3. Clinical pregnancy was based on the first hCG value reported if the data were available for both cycles.Results A final total of 47 women were eligible for inclusion with a mean interval of 362 ±368 days between the two ovum pick ups. The characteristics of their ICSI cycles before and after the vaccination were similar for all the parameters. Additionally, the number and percentage of clinical pregnancies did not significantly differ between the PRE and POST vaccination groups (n=15).Conclusion This study is the first to evaluate the impact of the BNT162b2 vaccine on women’s fertility. From our findings, the vaccine appears to have no impact on women’s fertility. This study is the first step in abolishing the misinformation derived from unreliable sources and reassuring patients in order to improve compliance and promote COVID-19 eradication.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board, Hadassah Medical Center IRB (Permit 0054-21-HMO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, MS, upon reasonable request.